drugset / Trial / NCT03593044

Side Effects of Atropine (SEA) Study

NCT03593044

Phase 1/2 Completed 31 enrolled Jeffrey J. Walline, OD PhD
NaSingle-groupOpen-labelTreatment

Summary

This study will perform several objective and subjective measurements of the eye and vision before and after a week of using 0.01% concentration atropine drops. These measurements will help to obtain a comprehensive understanding of the side effects of this concentration of atropine and determine if the drops would be tolerated as a possible preventative treatment for nearsightedness.

Timeline

Start
2018-07-23
Primary completion
2019-01-17
Completion
2019-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.01 % Other

Indications